Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr17.20 SEK
Change Today 0.00 / 0.00%
Volume 7.4K
OASM On Other Exchanges
Symbol
Exchange
Frankfurt
As of 11:29 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

oasmia pharmaceutical ab (OASM) Snapshot

Open
kr17.70
Previous Close
kr17.20
Day High
kr17.70
Day Low
kr16.80
52 Week High
02/27/15 - kr22.90
52 Week Low
06/29/15 - kr15.20
Market Cap
1.7B
Average Volume 10 Days
46.3K
EPS TTM
kr-1.28
Shares Outstanding
97.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OASMIA PHARMACEUTICAL AB (OASM)

Related News

No related news articles were found.

oasmia pharmaceutical ab (OASM) Related Businessweek News

No Related Businessweek News Found

oasmia pharmaceutical ab (OASM) Details

Oasmia Pharmaceutical AB (publ) researches, develops, and manufactures drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company’s drug candidates for human health include Paclical that has completed Phase III clinical trial for the treatment of ovarian cancer, as well as is in Phase I clinical trial for treating metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin in Phase I clinical trial for the treatment of cancer; Docecal, a patented formulation of cytostatic docetaxel, which is in pre-clinical stage for the treatment of breast cancer; and OAS-19 that is in pre-clinical stage to treat various cancers. Its product candidates for animal health comprise Paccal Vet-CA1, a formulation of paclitaxel for the treatment of mastocytoma, mammary carcinoma, and squamous cell carcinoma in dogs; and Doxophos Vet, a Phase I clinical trial product for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden.

79 Employees
Last Reported Date: 06/4/15
Founded in 1990

oasmia pharmaceutical ab (OASM) Top Compensated Officers

Co-Founder, Executive Chairman and Member of ...
Total Annual Compensation: kr1.3M
Compensation as of Fiscal Year 2014.

oasmia pharmaceutical ab (OASM) Key Developments

Oasmia Pharmaceutical AB (Publ) Announces Consolidated and Parent Earnings Results for the Fourth Quarter and Year Ended April 30, 2015

Oasmia Pharmaceutical AB (publ) announced consolidated and parent earnings results for the fourth quarter and year ended April 30, 2015. For the quarter, on consolidated basis, the company reported net sales of SEK 36,000 compared to SEK 20,000 a year ago. Operating loss was SEK 27,791,000 against SEK 35,239,000 a year ago. Loss before taxes was SEK 29,622,000 against SEK 37,790,000 a year ago. Loss for the period attributable to shareholders of the parent company was SEK 29,622,000 or SEK 0.30 per share before and after dilution against SEK 37,790,000 or SEK 0.45 per share before and after dilution a year ago. Cash outflow from operating activities was SEK 25,466,000 against SEK 26,481,000 a year ago. Investments in intangible fixed assets were SEK 3,584,000 against SEK 9,633,000 a year ago. Investments in property, plant and equipment were SEK 849,000 against SEK 1,878,000 a year ago. Net debt was SEK 30,010,000 against SEK 96,759,000 a year ago. For the full year, on consolidated basis, the company reported net sales of SEK 2,070,000 compared to SEK 60,000 a year ago. Operating loss was SEK 107,767,000 against SEK 98,091,000 a year ago. Loss before taxes was SEK 117,039,000 against SEK 105,112,000 a year ago. Loss for the period attributable to shareholders of the parent company was SEK 117,039,000 or SEK 1.28 per share before and after dilution against SEK 105,112,000 or SEK 1.27 per share before and after dilution a year ago. Cash outflow from operating activities was SEK 108,355,000 against SEK 86,899,000 a year ago. The decrease in cash flow from operating activities compared to the previous year is due to both lower operating income and negative changes in working capital. Investments in intangible fixed assets were 16,717,000 against SEK 33,545,000 a year ago. Investments in property, plant and equipment were SEK 3,621,000 against SEK 2,138,000 a year ago. For the quarter, on parent basis, the company reported net sales of SEK 36,000 compared to SEK 20,000 a year ago. Operating loss was SEK 27,786,000 against SEK 35,226,000 a year ago. Loss was SEK 29,692,000 against SEK 37,826,000 a year ago. Loss before tax was SEK 29,692,000 against SEK 37,826,000 a year ago. For the year, on parent basis, the company reported net sales of SEK 2,070,000 compared to SEK 60,000 a year ago. Operating loss was SEK 107,736,000 against SEK 98,025,000 a year ago. Loss was SEK 117,083,000 against SEK 105,126,000 a year ago. Loss before tax was SEK 117,083,000 against SEK 105,126,000 a year ago.

Oasmia Pharmaceutical AB Announces Executive Changes

Oasmia Pharmaceutical AB announced that at the extraordinary general meeting held on May 28, 2015 a resolution was made to elect Hans Liljeblad and Lars Bergkvist as new Members of the Board and that Julian Aleksov succeeds Joel Citron as Executive Chairman of the Board. Joel Citron resigned as Chairman of the Board in order to pursue his other commitments in the USA. He is succeeded by Julian Aleksov, former CEO of Oasmia and one of the founders of the company. Julian will work as Executive Chairman on a full-time basis focusing on corporate- and business development and strategy. Liljeblad and Lars Bergkvist were elected as new members of the Board.

Oasmia Pharmaceutical AB (publ), Special/Extraordinary Shareholders Meeting, May 28, 2015

Oasmia Pharmaceutical AB (publ), Special/Extraordinary Shareholders Meeting, May 28, 2015., at 14:00 Central European Standard Time. Location: floor 7, Vallongatan 1. Agenda: To consider election of board of directors; and to consider resolution on authorization for the board of directors to issue shares, warrants and/or convertible instruments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OASM:SS kr17.20 SEK 0.00

OASM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OASM.
View Industry Companies
 

Industry Analysis

OASM

Industry Average

Valuation OASM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 91.3x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 81.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OASMIA PHARMACEUTICAL AB, please visit www.oasmia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.